The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Kristin Brill named enterprise director of Breast Oncology at SKCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Breast surgeon Kristin L. Brill has joined the Sidney Kimmel Cancer Center–Jefferson Health as enterprise director of Breast Oncology.

Particular areas of focus for Brill include young women with breast cancer and those at high risk.

Brill joins SKCC from Cooper University Health Care, where she was head of the Division of Breast Surgery and Director of the Janet Knowles Breast Cancer Center at MD Anderson Cancer Center at Cooper and assistant professor of surgery at Cooper Medical School of Rowan University. She also directed the Breast Surgical Oncology Fellowship at Cooper Medical School and was an adjunct assistant professor in the Department of Surgery at MD Anderson Cancer Center.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account